{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:56:38Z","timestamp":1789764998420,"version":"4.0.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jns.2021.117622","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T17:19:16Z","timestamp":1629652756000},"page":"117622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic"],"prefix":"10.1016","volume":"429","author":[{"given":"Gerd Haga","family":"Bringeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Alexander","family":"Vedeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gavasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117622_bb0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2021.117622_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int. J. MS Care"},{"issue":"17","key":"10.1016\/j.jns.2021.117622_bb0015","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle; recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117622_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jns.2021.117622_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/cyto.b.21527","article-title":"Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients","volume":"94","author":"Punet-Ortiz","year":"2017","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.jns.2021.117622_bb0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of Natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2021.117622_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2021.117622_bb0040","doi-asserted-by":"crossref","first-page":"116880","DOI":"10.1016\/j.jns.2020.116880","article-title":"Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study","volume":"415","author":"Bringeland","year":"2020","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21003166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21003166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:56:03Z","timestamp":1758383763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":8,"alternative-id":["S0022510X21003166"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117622","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117622"}}